OSART is indicated for the treatment of hypertension, to lower blood pressure.
OSART blocks the vasoconstrictor effects of angiotensin II by selectively blocking the binding of angiotensin II to the AT1 receptor in vascular smooth muscle. Its action is, therefore, independent of the pathways for angiotensin II synthesis. OSART has more than a 12,500-fold greater affinity for the AT1 receptor than for the AT2 receptor.
Absolute bioavailability: approximately 26%. Cmax of OSART is reached after 1 to 2 hours. Food does not affect the bioavailability of it. The volume of distribution of OSART is approximately 17 L. It is highly bound to plasma proteins (99%) and does not penetrate red blood cells. Total plasma clearance of OSART is 1.3 L/h; with a renal clearance of 0.6 L/h. Approximately 35% to 50% of the absorbed dose is recovered in urine while the remainder is eliminated in feces via the bile. OSART appears to be eliminated in a biphasic manner with a terminal elimination half-life of approximately 13 hours.
Hypertension 10-20 mg once daily. Dose may be increase up to 40 mg once daily.
Available in 10/20mg tablet OSART 10 (Olmesartan 10 mg): 10 x 10s OSART 20 (Olmesartan 20 mg): 10 x 10s